ROCKVILLE, Md.

and

BEIJING

,

Sept. 20, 2021

/PRNewswire/ — CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that Dr.

Alexander Zukiwski

, Chief Medical Officer of CASI Pharmaceuticals, will be presenting at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. Details for the virtual conference is as follows.

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit


Date:

Tuesday, September 21


^st


Time:

12:05 PM (EDT)

Webcast or external link of the company presentation will be available under “Events & Presentations” in the “Investors Relations” section of CASI’s website. Archived replays will be available for approximately 90 days following the event.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in

China

,

the United States

, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the greater

China

market leveraging the Company’s

China

-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in

China

are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (

China

) Co., Ltd., which is located in

Beijing, China

. The Company has built a commercial team of more than 100 hematology and oncology sales and marketing specialists based in

China

. More information on CASI is available at

www.casipharmaceuticals.com

.

View original content to download multimedia:

https://www.prnewswire.com/news-releases/casi-pharmaceuticals-inc-to-participate-in-oppenheimer-fall-healthcare-life-sciences–medtech-summit-301379920.html

SOURCE CASI Pharmaceuticals, Inc.